Vizsgálati helyszín
Sigmedical Services S.R.L.
Suceava, 720214, RomániaEU-13 felzárkózó országMég nincs intézményhez kötve
- 16futó vizsgálat
- 9lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 25 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis19 vizsgálat
- 2. fázis5 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Lezárult9 vizsgálat
- Toboroz9 vizsgálat
- Fut, nem toboroz6 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Merck Sharp & Dohme LLC3 vizsgálat
- Arcus Biosciences, Inc.2 vizsgálat
- Daiichi Sankyo2 vizsgálat
- Glaxosmithkline Research & Development Limited2 vizsgálat
- Ribocure Pharmaceuticals AB2 vizsgálat
- és még 14
Futó vizsgálatok
Toboroz
Study to assess the safety, tolerability, and effects of vortosiran in two groups: participants who previously had a blood clot and completed initial blood-thinner treatment, and participants with cancer who are at high risk of blood clots
2026-525479-15-00· 2. fázis· Ribocure Pharmaceuticals AB· Forrás
Még nem toboroz
Vortosiran for VTE Prevention
NCT07850453· 2. fázis· Ribocure Pharmaceuticals AB· Forrás
Contact: Doina Elena Ganea, Professor
Toboroz
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152· 3. fázis· Immuneering Corporation· Forrás
Toboroz
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719· 3. fázis· Arcus Biosciences, Inc.· Forrás
Toboroz
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer
2024-513122-27-00· 3. fázis· Daiichi Sankyo Inc.· Forrás
Toboroz
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006· 3. fázis· Shanghai Henlius Biotech· Forrás
Toboroz
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT06345729· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squamous non-small cell lung cancer patients
2023-507448-36-00· 3. fázis· Samsung Bioepis Co. Ltd.· Forrás
Fut, nem toboroz
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
2023-503428-24-00· 2. fázis· Glaxosmithkline Research & Development Limited· Forrás
Fut, nem toboroz
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773· 3. fázis· Taiho Oncology, Inc.· Forrás
Toboroz
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
NCT05050942· 3. fázis· Camurus AB· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Fut, nem toboroz
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC
2023-504753-12-00· 3. fázis· Glaxosmithkline Research & Development Limited· Forrás
Lezárult
APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer)
2023-506975-83-00· 3. fázis· Aprogen Inc.· Forrás
Fut, nem toboroz
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575· 2. fázis· Mirati Therapeutics Inc.· Forrás
Lezárult
Efficacy and safety of the proposed biosimilar PERT-IJS versus EU-Perjeta® along with trastuzumab and chemotherapy (carboplatin and docetaxel) as neoadjuvant treatment in chemotherapy naïve patients with early stage or locally advanced HR negative and HER2 positive breast cancer
2023-506163-34-00· 3. fázis· Biocon Biologics UK Limited· Forrás
Fut, nem toboroz
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT05785767· 2/3. fázis· Regeneron Pharmaceuticals· Forrás
Lezárult
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
NCT05568095· 3. fázis· Arcus Biosciences, Inc.· Forrás
Toboroz
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
NCT05303532· 3. fázis· Astrazeneca AB· Forrás
Fut, nem toboroz
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
NCT04567615· 2. fázis· Bristol-Myers Squibb· Forrás
Hibát jelzek